WallStSmart

Cosmos Health Inc. (COSM)vsMcKesson Corporation (MCK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

McKesson Corporation generates 567920% more annual revenue ($418.79B vs $73.73M). MCK leads profitability with a 1.1% profit margin vs -33.1%. MCK earns a higher WallStSmart Score of 49/100 (D+).

COSM

Hold

36

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: -2.45

MCK

Hold

49

out of 100

Grade: D+

Growth: 7.3Profit: 4.5Value: 4.0Quality: 7.0
Piotroski: 5/9Altman Z: 5.40
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for COSM.

MCKSignificantly Overvalued (-54.6%)

Margin of Safety

-54.6%

Fair Value

$616.65

Current Price

$1105.04

$488.39 premium

UndervaluedFair: $616.65Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COSM1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
28.8%8/10

Revenue surging 28.8% year-over-year

MCK4 strengths · Avg: 9.3/10
Debt/EquityHealth
-2.8210/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
5.4010/10

Safe zone — low bankruptcy risk

Market CapQuality
$124.35B9/10

Large-cap with strong market position

Free Cash FlowQuality
$2.95B8/10

Generating 2.9B in free cash flow

Areas to Watch

COSM4 concerns · Avg: 3.3/10
Price/BookValuation
9.6x4/10

Trading at 9.6x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$20.89M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-106.6%2/10

ROE of -106.6% — below average capital efficiency

MCK4 concerns · Avg: 3.5/10
PEG RatioValuation
1.864/10

Expensive relative to growth rate

P/E RatioValuation
27.8x4/10

Moderate valuation

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
1.1%3/10

1.1% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : COSM

The strongest argument for COSM centers on Revenue Growth. Revenue growth of 28.8% demonstrates continued momentum.

Bull Case : MCK

The strongest argument for MCK centers on Debt/Equity, Altman Z-Score, Market Cap.

Bear Case : COSM

The primary concerns for COSM are Price/Book, EPS Growth, Market Cap.

Bear Case : MCK

The primary concerns for MCK are PEG Ratio, P/E Ratio, Return on Equity. Thin 1.1% margins leave little buffer for downturns.

Key Dynamics to Monitor

COSM profiles as a growth stock while MCK is a value play — different risk/reward profiles.

COSM carries more volatility with a beta of 4.44 — expect wider price swings.

COSM is growing revenue faster at 28.8% — sustainability is the question.

MCK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MCK scores higher overall (49/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cosmos Health Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Cosmos Holdings Inc. is a vertically integrated pharmaceutical company. The company is headquartered in Chicago, Illinois.

McKesson Corporation

HEALTHCARE · MEDICAL DISTRIBUTION · USA

McKesson Corporation is an American company distributing pharmaceuticals and providing health information technology, medical supplies, and care management tools.

Visit Website →

Want to dig deeper into these stocks?